This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date.
When we launched this resource in May 2019, companies with quarterly revenue in excess of US$2.5 million qualified.
We expect to add additional companies in the months ahead, and, due to pending or recently completed mergers, we anticipate some removals as well.
We note that often operating income can include one-time items like stock compensation, inventory write-downs or public listing expenses, and we recommend that readers understand how these non-cash items can impact quarterly financials.
Adding the Q1 Aphria revenue from a year ago and the Q2 Tilray revenue suggests that the company saw a 6% year-over-year decline in contrast to 49% growth in the overall Canadian adult-use market.
Looking to the first part of November, many of the largest American companies will be reporting financials, including Scotts Miracle-Gro , all of which reported revenue in excess of $125 million in Q2.
Verano Q3 revenue is expected to have increased 250% from a year ago, before the AltMed acquisition and several others, to $225 million, up 13% sequentially.
Finally, both Hydrofarm and GrowGeneration have already pre-announced disappointing Q3 results.
Its growth in adult-use sales during the quarter of 21% to C$29.8 million substantially trailed the 57% year-over-year growth in the overall Canadian market.
Aurora Cannabis Q1 revenue is expected to decline nearly 10% to C$61 million, with adjusted EBITDA expected to be -C$16 million.
For our readers who are interested in staying on top of scheduled earnings calls in the sector, we have have created and continually update the Cannabis Investor Earnings Conference Call Calendar.